After a review of current evidence by a panel of experts, the American Thoracic Society (ATS) has published new recommended guidelines for the use of oxygen therapy by people with chronic obstructive pulmonary disease (COPD) and other long-term…

The American Thoracic Society (ATS), through its Research Program and with support from 4DMedical, announced it will award three, $50,000 grants for research using a new, non-invasive technology to assess lung health. These one-year grant opportunities are focused on work into chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary…

New official guidelines have been published by the American Thoracic Society (ATS) for the treatment of chronic obstructive pulmonary disease (COPD). Among the new recommendations, the combination of long-acting beta two agonists (LABA) and long-acting muscarinic antagonists (LAMA) is recommended over either therapy alone to treat people with COPD…

A post-hoc analysis showed that nebulized ensifentrine (RPL544) is highly effective for relieving respiratory symptoms in chronic obstructive pulmonary disease (COPD) patients with either reversible or non-reversible airway obstruction, although the effect is greater for those with reversible disease, according to Verona Pharma, ensifentrine’s developer. Over a treatment…

Verona Pharma’s treatment candidate for chronic obstructive pulmonary disease (COPD) RPL554 works to open the airways of the lungs, aiding bronchodilation, when used with Spiriva (tiotropium), and its newer inhaled formulation is safe and appropriate for patient use, clinical trial data being presented at ATS 2018 report. RPL554 is designed…

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the United States. But while significant scientific progress is being made, COPD patients face serious challenges when it comes to treatment access, particularly because  treatments costs are high and hospitals have not yet reached recommended standards for COPD care. The startling opinions,…